Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
Data presented today at the 35th European Society for Medical Oncology Congress
###
ABOUT NOVOCURE
Novocure is a subsidiary of Jersey Isle based Standen Ltd., an oncology company pioneering tumor treating fields (TTF) therapy, a new modality for treating solid tumors. Novocure’s US operations are based in Portsmouth, NH and the company’s research center is located in Haifa, Israel. For additional information about Novocure, please visit www.novocuretrial.com.
EDITORS NOTE: High resolution device photos available by request.
1Nasser Hanna et al; "Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-Small-Cell Lung Cancer Previously TreatedWith Chemotherapy," Journal of Clinical Oncology 22.9 (2004): pp 1589-1597
END